```
prompt_version: stage1-v17-20260415
model_info: claude-sonnet-4-6

target_title:   Asymmetric Synthesis of Quaternary Hydantoins via a Palladium-Catalyzed Aza-Heck Cyclization
target_authors: Ellie A. Meck, Humair M. Omer, Montana J. Edwards, Temidayo D. Idowu, Mariah L. Murray, Katerina M. Korch, and Donald A. Watson
target_start:   page 1: [REDACTED: paper boundary quote; see Tier 9]
target_end:     end of document

[Agent fields]
V1: Asymmetric synthesis / palladium-catalyzed C–N bond-forming reactions — identifies absent scope, control, and reporting data from the synthetic organometallic perspective.
V2: Physical organic / mechanistic chemistry — interrogates the evidentiary basis for the proposed catalytic cycle and kinetic/thermodynamic control of enantioselectivity.
V3: Analytical chemistry / chromatography — evaluates data quality, measurement disclosure, and reproducibility of quantitative claims (yield, ee).

--- Step 0: Boundary recheck ---
All 35 quotes from Turns 1–3 fall within the single-paper PDF (pp. 44692–44698). No quotes reference chemistry or data from outside the target paper. No boundary violations found.

--- Classification ---

[A] A-01 | P3:Lcol:25* | [REDACTED: substantial verbatim quotation; see Tier 9] | deferred | mixed_detail: n/a | reason_inferred: T1 | linked_to: B-16, U-01 | cross_field_temperature: V1=high, V2=critical (V2-OV1); convergence=2/3; temperature_gap=low

[B] B-01 | P3:Lcol:1* | "10, 12%, 63% ee" [Scheme 3, Functional Groups series] | methodological_limitation | rhetorical_function: Scope example presented as part of the functional-group series without accompanying comment. | note: The 4-bromo substrate shows a 6-fold yield decrease and 34 percentage-point ee drop relative to adjacent benzyl analogues (5–9); no electronic, steric, or catalyst-deactivation rationale is offered. The bromo group could participate in competing Pd-mediated oxidative addition, but this is not stated in paper. | cross_field_temperature: V1 only; severity=high

[B] B-02 | P3:Rcol:1* | "19, 33%, 43% ee" [Scheme 3, Tetrasubstituted Alkenes series, 75 °C] | methodological_limitation | rhetorical_function: Scope example listed without comment within the tetrasubstituted-alkene sub-table. | note: Both yield (33%) and ee (43%) are far below the sub-table average; the paper provides no explanation. Flags: scope failure example without attribution. | cross_field_temperature: V1=high, V2=high (V2-OV4); convergence=2/3; temperature_gap=none

[B] B-03 | P3:Lcol:1* | "18, 99%, 63% ee²" [Scheme 3, Tetrasubstituted Alkenes series, footnote b: NMR yield] | reporting_omission / mixed | rhetorical_function: Scope example in tetrasubstituted-alkene sub-table with footnote indicating NMR yield at reduced scale. | note: NMR yield (99%) is presented without corresponding isolated yield, making this entry non-comparable to others reported as isolated yields; separately, the 63% ee is unexplained relative to 86–97% ee for the standard benzyl scope. Flags: metric incompleteness (NMR vs isolated), yield-basis mixing exception applies. | cross_field_temperature: V1=high, V3=high (V3-OV3); convergence=2/3; temperature_gap=none

[B] B-04 | P3:Rcol:20* | [REDACTED: substantial verbatim quotation; see Tier 9] [footnote 23] | methodological_limitation | rhetorical_function: Footnote acknowledging complete failure for a substrate class with SI referral. | note: The paper acknowledges the failure but provides no electronic, steric, or conformational rationale in the main text or inferred from the SI citation. What was observed (unreacted SM, decomposition, catalyst inhibition) is not stated. Flags: negative result as evidence (absence of reaction cited to narrow scope without explanation).

[B] B-05 | P3:Lcol:20* | [REDACTED: substantial verbatim quotation; see Tier 9] [Scheme 4] | mixed (methodological_limitation + reporting_omission) | rhetorical_function: Attribution of ee erosion at higher catalyst loading to racemic byproduct conversion, supporting the Heck-pathway preference. | note: (1) The mechanism by which racemic 26 converts to enantioselective 5 is not described — no rate data, no stoichiometric control experiment, no isotopic labeling. (2) No non-linear effect (NLE) study was performed; without NLE data, the role of bis- vs. mono-ligated Pd in the enantiodetermining step cannot be evaluated. (3) No time-resolved chiral HPLC monitoring of 5 and 26 is reported to quantify the conversion kinetics. Self-contradictory absence sub-aspect: the paper's mechanistic model predicts that this conversion proceeds with some stereospecificity, but this is neither measured nor acknowledged as untested. Flags: negative result as evidence, metric incompleteness. | cross_field_temperature: V1=medium, V2=high (V2-OV2), V3=medium (V3-OV4); convergence=3/3; temperature_gap=low

[B] B-06 | P2:Rcol:10* | [REDACTED: substantial verbatim quotation; see Tier 9] [Scheme 3, compound 6 footnote] | reporting_omission | rhetorical_function: Gram-scale datum appended as footnote to a scope entry. | note: 31% yield at gram scale vs. 78% at 0.5 mmol represents a 2.5-fold decrease; no explanation (concentration effect, heat transfer, catalyst decomposition) is provided. It is not stated whether this is an isolated yield, whether starting material was recovered, or how purity was confirmed. | cross_field_temperature: V1=medium, V3=high (V3-OV2); convergence=2/3; temperature_gap=low

[B] B-07 | P3:Rcol:25* | [REDACTED: substantial verbatim quotation; see Tier 9] [Scheme 5] | reporting_omission | rhetorical_function: Improved-conditions variant for the key demonstration substrate en route to mephenytoin. | note: (1) The basis for the absolute configuration assignment of 29 (and the final (R)-mephenytoin) is not stated in the main text — SXRD, VCD, optical rotation, or comparison with authentic standard are all plausible but none is specified. For a claimed "first asymmetric synthesis," configuration assignment evidence is a primary datum. (2) The ee of the final mephenytoin product (after the LiHMDS/H₂ and allylation steps following cyclization) is not reported; it is unknown whether 91% ee is retained through these operations. | cross_field_temperature: V3=high (V3-Q3), V1=medium (V1-Q11); convergence=2/3; temperature_gap=low

[B] B-08 | loc: not recoverable | "up to 98% ee" [Abstract]; ee values listed throughout Scheme 3 | reporting_omission | rhetorical_function: Headline selectivity claim in abstract and substrate scope data. | note: The method used to determine ee (chiral HPLC column identity, SFC conditions, or NMR chiral shift reagent) is not stated for any of the 21 scope products in the main text. Without this disclosure, cross-compound ee comparisons and independent verification are not possible.

[B] B-09 | P3:Rcol:28* | "using the novel (S)-spinol-(S)-1-amino-indane-derived ligand L9" [Scheme 5] | reporting_omission | rhetorical_function: Introduction of an alternative chiral ligand for the demonstration synthesis. | note: L9 is deployed for only one substrate (27 → 29). Its source (commercial, synthesized in-house), structural features, and whether it was screened against any of the 21 general-scope substrates are not stated. It is not established whether L9 is superior to L1 for the broad substrate class. | cross_field_temperature: V1 only; severity=medium

[B] B-10 | P2:Lcol:1* | [REDACTED: substantial verbatim quotation; see Tier 9] [Table 1, entry 5] | reporting_omission | rhetorical_function: Standard conditions statement for the optimal catalyst system. | note: (1) Pd(OAc)₂ is a Pd(II) pre-catalyst, but the proposed cycle invokes Pd(0) as active species. No pre-activation step, induction period, Pd(0) source, or evidence for heterogeneous vs. homogeneous catalysis is discussed. (2) The enantiomeric purity of commercially obtained L1 is not stated; for a phosphoramidite ligand, the ligand ee sets an upper bound on product ee. | cross_field_temperature: V2=medium (V2-Q2), V3=medium (V3-Q6); convergence=2/3; temperature_gap=none

[B] B-11 | P3:Lcol:1* | [REDACTED: substantial verbatim quotation; see Tier 9] [Scheme 3 footnotes] | reporting_omission | rhetorical_function: Footnote disclosing the dual yield-determination basis for the scope table. | note: Scheme 3 mixes isolated yields (most entries, 0.5 mmol scale) with NMR yields (footnote b, 0.1 mmol scale) without per-compound disclosure of which method applies to each entry. This creates an internally inconsistent yield-reporting basis. Per the yield-basis mixing exception to the consolidation rule, this is retained as a separate B item. Flags: metric incompleteness, yield-basis mixing. | cross_field_temperature: V3 only; severity=medium

[B] B-12 | P2:Lcol:15* | [REDACTED: substantial verbatim quotation; see Tier 9] [optimization section] | reporting_omission | rhetorical_function: Qualitative summary of base/acid screening outcome from the optimization. | note: nBu₂N is selected without a pKaH series. It is unknown whether the base deprotonates the N–H to generate the N-Pd bond, acts as an HX scavenger after β-hydride elimination, or serves a kinetically distinct role. The stoichiometry (5 equiv) is not rationalized. | cross_field_temperature: V2 only; severity=medium

[B] B-13 | P3:Lcol:30* | [REDACTED: substantial verbatim quotation; see Tier 9] [Figure 3 discussion] | reporting_omission | rhetorical_function: Mechanistic preference statement invoking N–O bond activation. | note: Scheme 1 shows substrate preparation as a trichloroacetimidate or phenoxyacetate N–O species; the paper does not specify which N–O bond is the site of oxidative addition, nor whether trichloroacetimidate and aryloxy substrates undergo the same elementary first step. This ambiguity is unacknowledged. | cross_field_temperature: V2 only; severity=medium

[B] B-14 | loc: not recoverable | Yield and ee values throughout Scheme 3 (21 examples) | reporting_omission | rhetorical_function: Primary quantitative evidence for the scope claim. | note: No duplicate experiments or error ranges are reported for any yield or ee value. In asymmetric catalysis, ee values near the ceiling (97–99%) are especially sensitive to small weighing and integration errors; without replicate data the precision of these values cannot be assessed. | cross_field_temperature: V3 only; severity=medium

[B] B-15 | P3:Lcol:15* | [REDACTED: substantial verbatim quotation; see Tier 9] [Scheme 4 discussion] | reporting_omission | rhetorical_function: Mechanistic commentary noting occasional observation of byproduct. | note: The amount of aza-Wacker byproduct 26 is quantified (5%) only for the model substrate (compound 4 in Scheme 4); Scheme 3 does not report byproduct amounts for any of the 21 scope entries. Without these data, mass balance and the extent of competing pathways across the scope are unknown. | cross_field_temperature: V1 only; severity=medium

[B] B-16 | P1:Lcol:40* | [REDACTED: substantial verbatim quotation; see Tier 9] | methodological_limitation | rhetorical_function: Computational support offered for the conformational basis of N-substituent-dependent reactivity. | note: The 0.6 kcal/mol figure is a ground-state substrate conformational energy difference, not a transition-state energy difference. Ground-state stability of reactant conformers does not directly determine kinetic selectivity (activation energy). Using this value as an explanation for N-Me substrate superiority conflates thermodynamic ground-state stability with kinetic control; this equivocation is not acknowledged in the paper. The level of theory, software, and conformers included in the calculations are not stated. | cross_field_temperature: V1=medium, V2=high (V2-OV3); convergence=2/3; temperature_gap=low

[B] B-17 | P2:Rcol:5* | [REDACTED: substantial verbatim quotation; see Tier 9] | reporting_omission | rhetorical_function: Summary statement crediting HTS screen for identifying the optimal ligand. | note: The number of ligands screened, structural classes included, screening criterion (yield, ee, or composite), and screening scale are not stated. Table 1 contains 5 entries representing optimization of solvent and temperature, but the full parameter space explored is opaque. | cross_field_temperature: V1=low (V1-Q15), V3=low (V3-Q4); convergence=2/3; temperature_gap=none

[C] C-01 | P1:Rcol:25* | Ref [10] (Archambeau et al., most recent multicomponent route — [REDACTED: substantial verbatim quotation; see Tier 9]) | textual_function: Cited as the most advanced prior method to motivate the present work, described with structural limitations that the present method claims to overcome. | reason_severed: Dropped Quantitative Benchmark — described as demonstrating "good to modest ee[REDACTED: substantial verbatim quotation; see Tier 9]good to modest") rather than a numerical benchmark, weakening the advance claim. | symmetric_pattern: partial (refs [7–9] are also cited with qualitative limitations but involve different chemistry)

[C] C-02 | P1:Rcol:15* | Refs [11–14] (prior enantioselective aza-Heck reactions, Figure 2A) | textual_function: Cited as evidence that "known asymmetric aza-Heck reactions are frequently limited in scope," illustrated in Figure 2A. | reason_severed: Specific yields, ee values, and substrate scope sizes from refs [11–14] are not cited numerically; no direct metric comparison with the present work's 21-example scope and up-to-99% ee is made. | affects_claims: medium — the claim that prior aza-Heck methods are scope-limited would be strengthened by numerical comparison. | symmetric_pattern: yes (all four refs are cited collectively as a class with the same rhetorical function)

[C] C-03 | P3:Rcol:28* | Ref [27] (Atkinson et al., pseudoephedrine-directed asymmetric α-arylation — cited as "only prior asymmetric synthesis" of mephenytoin core using "chiral-auxiliary approach") | textual_function: Cited to establish priority for the first enantioselective synthesis of mephenytoin without a chiral auxiliary. | reason_severed: No step count, overall yield, ee, or material economy comparison between Atkinson's route (ref [27]) and the present aza-Heck route is presented; the claim of improvement over prior art is qualitative only. | affects_claims: yes — the utility demonstration rests on superiority over ref [27], but no direct comparison quantifies this superiority. | symmetric_pattern: no

[U] U-01 | P3:Lcol:25* | [REDACTED: substantial verbatim quotation; see Tier 9] | Question: The paper proposes a complete catalytic cycle invoking three distinct Pd intermediates (Pd(0), a palladacycle, and a Pd-H species) and states a preference for this cycle over the aza-Wacker pathway. However, no intermediate was characterized or trapped, no kinetic experiment identifies the rate-determining step, and the sole mechanistic evidence — the racemicity of aza-Wacker byproduct 26 — rules out only the competing pathway without positively supporting any step of the Heck cycle. The paper thus "favors" a mechanism whose own proposed cycle predicts specific observable intermediates, without attempting to observe them. | originating_agent: V1-Q7 + V2-Q1 | severity: critical | note: Self-contradictory absence — the paper's proposed aza-Heck catalytic cycle (Figure 3) predicts at minimum a Pd-N species (from N–O oxidative addition) and a palladacycle intermediate, yet neither is characterized, trapped, or sought. The paper uses Figure 3 both as mechanistic justification for the Heck preference and as a deferred hypothesis requiring future computation, creating a logical gap between the mechanistic claim and its evidentiary status. This cannot be classified as A (no data are promised for these intermediates), B (the omission is self-undermining, not merely a reporting gap), or C (no citation is involved).

[META]
  linked_items:
    - A-01 ↔ B-16: A-01 defers TS-level understanding; B-16 reveals the paper's proxy (ground-state conformer energy) is mechanistically invalid as a TS surrogate.
    - A-01 ↔ U-01: Both concern the proposed mechanism in Figure 3; A-01 addresses deferred stereocontrol specifically, U-01 addresses the broader absence of evidence for any elementary step.
    - B-05 ↔ B-15: Both concern aza-Wacker byproduct 26 — B-05 addresses the conversion mechanism and ee implications; B-15 addresses undisclosed byproduct amounts across the scope.
    - B-07 ↔ C-03: The claim of "first asymmetric synthesis of (R)-mephenytoin" (B-07, missing config assignment evidence) depends on ref [27] (C-03, severed citation) for the priority claim.
    - B-01 ↔ B-04: Both are unexplained scope failures (4-bromo substrate and N,N-dialkyl substrates).

  same_root_groups:
    - SRG-1 [mechanism absent]: A-01, B-16, U-01 — share root: experimental and computational evidence for the proposed aza-Heck catalytic cycle and its stereocontrol is entirely absent.
    - SRG-2 [scope outliers unexplained]: B-01, B-02, B-03, B-04 — share root: substrates with anomalous or failed outcomes are presented without mechanistic or experimental rationalization.
    - SRG-3 [aza-Wacker byproduct]: B-05, B-15 — share root: the aza-Wacker byproduct 26 is invoked mechanistically but its quantitative behavior (amount, conversion, stereochemical fate) is unreported across the scope.
    - SRG-4 [quantitative claim disclosure]: B-08, B-11, B-14 — share root: quantitative claims (ee, yield) lack the methodological disclosure (determination method, yield basis, reproducibility) needed to evaluate them.
    - SRG-5 [scale/utility claim]: B-06, B-07 — share root: both synthetic utility demonstrations (gram-scale scope, mephenytoin first synthesis) carry unreported or unexplained quantitative gaps.
    - SRG-6 [optimization opacity]: B-17 — standalone; the ligand/condition screening process is not described in sufficient detail to assess whether the reported optimum was the global optimum.

  symmetric_citations: C-02 (refs [11–14] cited as a group, same rhetorical function)

  unreported_data:
    - Aza-Wacker byproduct amounts for 21 scope compounds (referenced as "several" in text but not quantified in Scheme 3)
    - Absolute configuration assignment method for mephenytoin intermediate 29 (stated outcome but method not disclosed)
    - ee of final (R)-mephenytoin product after post-cyclization steps
    - ee determination method for all 21 scope products
    - Per-compound yield-determination basis (isolated vs. NMR) for Scheme 3
    - Enantiomeric purity of commercial ligand L1

  series_signal: no

[TEMPERATURE_SUMMARY]
  high_convergence_high_gap: []

  high_convergence_low_gap:
    - A-01 (V1=high, V2=critical; convergence=2/3; temperature_gap=low)
    - B-02 (V1=high, V2=high; convergence=2/3; temperature_gap=none)
    - B-03 (V1=high, V3=high; convergence=2/3; temperature_gap=none)
    - B-05 (V1=medium, V2=high, V3=medium; convergence=3/3; temperature_gap=low)
    - B-06 (V1=medium, V3=high; convergence=2/3; temperature_gap=low)
    - B-07 (V3=high, V1=medium; convergence=2/3; temperature_gap=low)
    - B-16 (V1=medium, V2=high; convergence=2/3; temperature_gap=low)

  low_convergence_high_gap: []

[GAP]
  GAP-01 | type 1 | priority: high | description: Retrieve Archambeau et al. ref [10] to obtain specific ee values and substrate scope for direct numerical comparison with the present method's selectivity claims. | candidate_paper: Archambeau et al. (ref 10, multicomponent hydantoin synthesis with quaternary C5) | inference_label: T1 | status: pending

  GAP-02 | type 1 | priority: medium | description: Retrieve refs [11–14] (prior enantioselective aza-Heck reactions) to obtain specific ee/yield numbers for comparison with the 21-example scope reported here. | candidate_paper: refs [11–14] | inference_label: T1 | status: pending

  GAP-03 | type 3 | priority: high | description: Computational study of the diastereomeric transition states in the migratory insertion step would answer A-01 and provide quantitative basis for the stereocontrol claims; authors acknowledge this as ongoing work. | candidate_paper: forthcoming from Watson group (stated as "currently ongoing") | inference_label: T1 | status: pending

  GAP-04 | type 1 | priority: medium | description: Retrieve Atkinson et al. ref [27] (pseudoephedrine-directed mephenytoin synthesis) to enable step-count, yield, and ee comparison with the present first-enantioselective-synthesis claim. | candidate_paper: Atkinson et al., Angew. Chem. Int. Ed. 2015, 54, 8961–8965 | inference_label: T1 | status: pending

inference_time_sec: not available — inject externally
```

---

> **Tier 8 redaction notice**: This file is a redacted copy of the corresponding Tier 3 / Tier 9 output. Verbatim source-paper quotations have been replaced by `[REDACTED: see source paper §<loc>; full text retained in Tier 9 reviewer-only deposit]` markers, preserving location references and our own analytical content. Bibliographic fields (title, authors, journal, year, DOI), analytical labels (`evidence_chain:` with B-/U-/A-/C- internal IDs), short technical terms, and our own analytical text are not redacted. The redaction was applied by `scripts/redact_for_tier8.py` and, for this version, by `scripts/build_paperA_R1_public.py` with `scripts/redact_source_ngram_runs.py` (scripts of the project repository; they are not deposited).
